Boston, MA 02/11/2014 (wallstreetpr) – American Airlines Group Inc (NASDAQ:AAL): The benefit of combining American Airlines and US Airways to get AAL has started showing. January data show that the combined entities carried more passengers on longer distance that the same duration a year ago when you add the data from each of the companies when they were still operating as different business. AAL realized total revenue passenger miles of 17.3 million for the month of January, an increase of 3.8 percent over January 2013, according to documents filed with SEC. You calculate revenue passenger miles by multiplying number of miles traveled by the number of paying passengers. The revenue passenger miles for the combined company grew by 2.9 percent domestically and 6.7 percent for international flights. The stock of American Airlines Group Inc (NASDAQ:AAL) lost 9 cents per share in Monday’s trading to close at $35.58.
Newmont Mining Corp (NYSE:NEM) now carries consensus “hold” rating and $27.45 price objective. This follows views from 11 analysts where by two have rated the stock a “sell” while 8 have a “hold” rating on the stock. One of the analysts has assigned the stock “buy” rating. The latest firm to issue sentiment on the stock is Credit Suisse that restated its “neutral” rating on the stock, but lowered its price target to $21, down from the previous target of $28. Newmont Mining Corp (NYSE:NEM) which is primarily a gold producer runs operations and owns assets in many locations in the world. The stock gained 3.16 percent to add 68 cent on each of its share, thus closing at $22.20.
Galena Biopharma Inc (NASDAQ:GALE): This week has began on a positive note for GALE. The stock boosted its market value by 9.33 percent on Monday to hit $5.39 per share. The Monday success was yet another breach in the stock’s fall out which was witnessed last week following the company’s lack of guidance on its new hepatitis C drug, Sovaldi. The return of strength in the stock of Galena Biopharma Inc (NASDAQ:GALE) is indication that investors are gaining confidence in the stock even though they needed to see yearly sales projections for the new drug.
